Document is current
Any future updates will be listed below
-
Authors
Jung, Erik http://orcid.org/0000-0002-5016-8202
Osswald, Matthias
Ratliff, Miriam
Dogan, Helin
Xie, Ruifan
Weil, Sophie
Hoffmann, Dirk C.
Kurz, Felix T.
Kessler, Tobias http://orcid.org/0000-0001-8350-7074
Heiland, Sabine
von Deimling, Andreas http://orcid.org/0000-0002-5863-540X
Sahm, Felix http://orcid.org/0000-0001-5441-1962
Wick, Wolfgang http://orcid.org/0000-0002-6171-634X
Winkler, Frank http://orcid.org/0000-0003-4892-6104
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG, SFB 1389, DFG, SFB 1389, DFG, SFB 1389, DFG, SFB 1389, DFG, SFB 1389, DFG, SFB 1389, DFG, SFB 1389, DFG, SFB 1389)
- License Information
-
More Information
Article History
Received: 30 June 2020
Accepted: 8 January 2021
First Online: 12 February 2021
Competing interests
: E.J., M.O., W.W. and F.W. report the patent (WO2017020982A1) “Agents for use in the treatment of glioma”. F.W. is co-founder of DC Europa Ltd (a company trading under the name Divide & Conquer) that is developing new medicines for the treatment of glioma. Divide & Conquer also provides research funding to F.W.’s lab under a research collaboration agreement. All other authors declare no competing interests.
